Literature DB >> 28035208

Regulatory T Cells in Hepatitis B and C Virus Infections.

Min Kyung Jung1, Eui-Cheol Shin1.   

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are hepatotropic viruses that establish chronic persistent infection by effectively escaping the host immune response and can cause immune-mediated liver injury. It has recently become apparent that regulatory T (Treg) cells, specifically CD4+CD25+Foxp3+ Treg cells, modulate viral diseases by suppressing antiviral immune responses and regulating inflammatory host injury. The roles of Treg cells in HBV and HCV infections range from suppressing antiviral T cell responses to protecting the liver from immune-mediated damage. This review describes Treg cells and subpopulations and focuses on the roles of these cells in HBV and HCV infections.

Entities:  

Keywords:  Hepatitis B virus; Hepatitis C virus; Regulatory T cell

Year:  2016        PMID: 28035208      PMCID: PMC5195842          DOI: 10.4110/in.2016.16.6.330

Source DB:  PubMed          Journal:  Immune Netw        ISSN: 1598-2629            Impact factor:   6.303


INTRODUCTION

Hepatitis B virus (HBV) is a member of the family Hepadnaviridae, whereas hepatitis C virus (HCV) is a member of the family Flaviviridae. Both HBV and HCV are hepatotropic viruses that cause liver inflammation (123). These viruses can establish chronic persistent infections that are accompanied by immune-mediated liver injury in the infected host. The infection evolves to chronic persistent infection in more than 70% of HCV-infected adults and approximately 90% of HBV-infected neonates due to vertical transmission (4). Infected patients have a high risk of developing liver cirrhosis and hepatocellular carcinoma once a chronic persistent infection is established by either HBV or HCV (5). It has been demonstrated that virus-specific T cell responses are critical for the control of virus during HBV or HCV infection (6). In particular, adequate T cell responses are essential for spontaneous resolution of acute HBV or HCV infection and to prevent chronic persistent infection (37). Indeed, depletion of either CD4+ or CD8+ T cells disturbs viral clearance in challenge experiments with HBV or HCV in chimpanzees (8910). However, T cells also contribute to liver injury during HBV and HCV infection. In particular, the finding that intrahepatic infiltration of T cells coincides with the increase of serum alanine aminotransferase (ALT) levels during acute HBV or HCV infection supports the important role of T cells in liver injury (4711). However, the exact mechanism of T cell-mediated liver injury has not been elucidated. CD4+CD25+Foxp3+ regulatory T (Treg) cells constitute a specialized T cell population that suppresses the activation, proliferation, differentiation, and effector functions of many types of immune cells, including T cells, B cells, NK cells, and dendritic cells (12131415). Treg cells play an important role in the maintenance of immunologic tolerance by suppressing autoreactive T cells. In addition, Treg cells control excessive immune activation after infection with various pathogens. Indeed, Treg cells play an important role in the modulation of antiviral T cell responses and immune-mediated host injury in the acute and chronic phases of viral infection (161718). This review summarizes the current knowledge on Treg cells and their subpopulations and describes their role in HBV and HCV infections.

CD4+CD25+FOXP3+ TREG CELLS AND SUBPOPULATIONS

Although the concept of immune-suppressing T cell subsets was introduced in 1985 on the basis of their critical role in preventing autoimmunity (19), research on this T cell subset was hampered by the lack of a defining marker. In 1995, Sakaguchi et al. described a Treg population that constitutively expressed the interleukin 2 receptor α-chain (CD25) (20). In that study, the adoptive transfer of lymphocytes depleted of CD4+CD25+ T cells into athymic mice induced the development of autoimmune diseases. Interestingly, reconstitution with CD4+CD25+ T cells prevented autoimmune progression in these mice, suggesting a role for CD4+CD25+ T cells in the control of self-tolerance. CD4+CD25+ T cells in humans were found to have a similar function. Foxp3 was subsequently identified as the master regulator that determines the phenotype and function of CD4+CD25+ Treg cells (21). Treg cells are classified based on their mechanism of development. CD4+CD25+Foxp3+ Treg cells are divided into natural Treg (nTreg) cells or thymus-derived Treg cells and induced Treg (iTreg) cells or peripherally derived Treg cells (2223). nTreg cells develop during the process of T cell maturation in the thymus under T cell receptor engagement with self-antigens. nTreg cells suppress the activation and proliferation of T cells through contact-dependent mechanisms and have a key role in the maintenance of self-tolerance (24). Conversely, iTreg cells are generated de novo from conventional mature CD4+ T cells in the periphery in response to TGF-β and continuous exposure to low-dose antigen or systemic antigen (24252627). In addition to CD4+CD25+Foxp3+ Treg cells, CD4+ T cells producing IL-10 (Tr1) or TGF-β (Th3) and CD4+FoxA1+ T cells are considered regulatory cells (2829). Furthermore, CD8+ Treg cells have been described in both humans and mice (3031). In humans, Miyara et al. described three distinct subpopulations of CD4+CD25+Foxp3+ Treg cells that could be classified into the following populations based on their expression levels of CD45RA and Foxp3: CD45RA+Foxp3low resting Treg cells (subpopulation I), CD45RA−Foxp3high activated Treg cells (subpopulation II), and CD45RA−Foxp3low cytokine-secreting non-suppressive cells (subpopulation III) (Fig. 1) (32). A recent study has suggested CD15s as a new marker in the detailed analysis of Treg cell subpopulations. CD15shigh Treg cells are activated and terminally differentiated; thus, these cells are the most suppressive type of Foxp3+ effector Treg cells (33). A recent study showed that the frequency of CD45RA–Foxp3high activated Treg cells was increased in patients with chronic active hepatitis B and acute-on-chronic liver failure and correlated with HBV DNA titer (34). In addition, the frequency of CD45RA−Foxp3low cytokine-secreting non-suppressive cells was increased in patients with acute-on-chronic liver failure and correlated with severe liver injury (34). These data indicate that analyses of the Treg cell subpopulation better delineate disease status than analyses of the total Treg cell population.
Figure 1

The subpopulation of human Treg cells. Three distinct subpopulations of human Treg cells are defined based on the expression level of CD45RA and Foxp3 as follows: CD45RA+Foxp3low resting Treg cells (subpopulation I), CD45RA−Foxp3high activated Treg cells (subpopulation II), and CD45RA−Foxp3low cytokine-secreting non-suppressive cells (subpopulation III) (32).

TREG CELLS IN VIRAL INFECTION

Treg cells play a crucial role in suppressing immune responses to self-antigens and in controlling autoimmune diseases. However, Treg cells also modulate immune responses to infectious pathogens, including bacteria, viruses, parasites, and fungi (35). It has been shown that Treg cells regulate effector T cell responses against viruses such as herpes simplex virus (HSV), human immunodeficiency virus (HIV), and simian immunodeficiency virus (SIV) (173637). Effective virus-specific T cell responses are critical for eliminating the virus. However, several viruses can escape the T cell response and promote viral persistence. Treg cells play a role in the suppression of antiviral T cell responses during this process and aid the establishment of viral persistence. In viral infection, Treg cells also contribute to host protection by preventing excessive immunopathological host damage caused by sustained immune activation and inflammation (3839). For example, the role of Treg cells was clearly described in a murine model of corneal HSV infection (16). In this study, depletion of Treg cells prior to HSV challenge resulted in more severe eye inflammation by enhanced effector T cell infiltration. Furthermore, adoptive transfer of Treg cells reduced the severity of eye inflammation, indicating that Treg cells play a beneficial role by suppressing immunopathology and inflammation during viral infection.

TREG CELLS IN HBV INFECTION

Most studies of Treg cells in HBV infection have focused on the chronic phase of the infection, and it remains controversial whether the circulating CD4+CD25+ Treg cell population is expanded in patients with chronic HBV infection (40). Several studies have found a higher frequency of CD4+CD25+ Treg cells in HBV-infected individuals than in spontaneously recovered individuals or healthy controls (4142) although another study reported similar Treg cell frequencies in patients with chronic HBV infection and healthy controls (43). One study analyzed Treg cells in detail at each stage of HBV infection, including the acute, chronic, and chronic severe hepatitis B stages, and the patients with chronic severe hepatitis B showed a significantly higher frequency of circulating CD4+CD25+ Treg cells than those with chronic mild hepatitis B or acute hepatitis B (44). Furthermore, the patients with chronic severe hepatitis B also showed more CD4+CD25+Foxp3+ Treg cells in the liver (44). Interestingly, the frequency of circulating Treg cells was positively correlated with the serum HBV load in patients with chronic hepatitis B. This result suggests that the expanded Treg cell population suppresses antiviral immune responses during chronic HBV infection (4445). The mechanisms underlying the increase in Treg cell frequency in patients with chronic HBV infection have not been clearly elucidated. One hypothesis is that iTreg cells are induced by cytokines or continuous exposure to HBV antigens. A previous study proposed that TGF-β increases the frequency of Treg cells in patients with chronic HBV infection and that the serum TGF-β level is positively correlated with Treg cell frequency (46). TGF-β is known to promote the peripheral conversion of conventional CD4+ T cells to Treg cells (47). The major source of TGF-β in the liver is hepatic stellate cells (HSCs), which are activated during chronic inflammation (48). Therefore, persistent infection with HBV might lead to TGF-β production from HSCs and contribute to the differentiation of conventional CD4+ T cells into iTreg cells.

TREG CELLS IN HCV INFECTION

There are limited data describing Treg cells in acute HCV infection, which commonly leads to persistent infection. One study compared circulating Treg cells in patients with acute HCV infection who progressed to chronic infection with those in patients who spontaneously resolved the infection (49). The results demonstrated that chronic progression was associated with long-term maintenance of Treg cells, whereas spontaneous recovery in the acute stage was associated with temporal loss of the suppressive function of Treg cells. This result suggests that Treg cells are key determinants of spontaneous resolution vs chronic progression of acute HCV infection. Several studies of patients with chronic HCV infection revealed an increased frequency of CD4+CD25+ Treg cells in the peripheral blood compared with spontaneously resolving patients or healthy controls (505152). Increased Treg cell frequencies in the liver have also been observed in chronically infected patients (5354). However, it is uncertain whether these Treg cells are nTreg or iTreg cells induced by HCV antigens. Interestingly, Treg cells from chronically infected patients exhibit significantly higher suppressive activity against T cell proliferation and IFN-γ secretion (55). However, Treg cells from HCV-infected individuals inhibit CD8+ T cells in an antigen-nonspecific manner and suppress not only HCV-specific T cells but also influenza-, CMV-, and EBV-specific T cells (5355). Ward et al. studied the distribution of Treg cells within the HCV-infected liver by defining Treg cells as Foxp3+ and CD4+ cells, and the results showed a large amount of Treg cell infiltration in persistently HCV-infected patients than in healthy individuals. This finding suggests the involvement of CD4+Foxp3+ cells in intrahepatic immune regulation (54). Another studies have demonstrated that CD4+Foxp3+ Treg cells play a pivotal role in the protection against tissue damage by suppressing excessive HCV-induced immune activation (56). In this study, there was an increased number of Treg cells in chronic HCV-infected livers with limited fibrosis. In addition, HCV-specific CD4+CD25+ Treg cells from chronic HCV patients with normal serum ALT levels produced consistently higher amounts of TGF-β than Treg cells from chronic HCV patients with elevated ALT levels (57). These results suggest a role for these cells in controlling the chronic inflammatory response and hepatic damage. One study showed that CD4+CD25+Foxp3+ Treg cells suppress not only IFN-γ production and the proliferation of HCV-specific T cells but also activation-induced cell death of HCV-specific T cells in HCV-exposed chimpanzees, including both hosts spontaneously recovered from HCV infection and hosts with chronic HCV infection (58). Therefore, it was suggested that Treg cells might control HCV-specific memory T cell responses by limiting their activation and preventing apoptosis in hosts who have recovered from HCV infection. A detailed analysis of the CD4+CD25+ Foxp3+ population in chimpanzees revealed that Treg cells from chronically infected and recovered chimpanzees displayed fewer T cell receptor excision circles than Treg cells from HCV-naïve chimpanzees, indicating that the cells underwent more proliferation as a result of HCV infection. In addition to CD4+CD25+Foxp3+ Treg cells, CD8+ T cells with regulatory functions have been studied in patients with HCV infection. HCV-specific CD8+ T cells that produce IL-10 were identified in the livers of chronically infected patients by in situ immunostaining (59). Previous studies have demonstrated that IL-10-producing CD8+ T cells protect against liver cirrhosis by reducing hepatocellular apoptosis, indicating their role in decreasing liver damage (59). Accapezzato et al. showed that the anti-viral function of HCV-specific effector CD8+ T cells infiltrating the liver was not efficient in patients with chronic HCV infection because of the concomitant presence of virus-specific CD8+ T cells producing considerable amounts of IL-10 (60). This finding suggests that IL-10-producing CD8+ T cells contribute to viral persistence by controlling hepatic effector CD8+ T cell responses. TGF-β-secreting, HCV-specific CD8+ T cells were also identified in the blood of patients with chronic HCV infection (61). When TGF-β secretion was blocked, the peripheral HCV-specific T cell responses were enhanced despite the presence of HIV co-infection.

CONCLUSIONS

The function of Treg cells may be a double-edged sword in hepatitis viral infections. Although Treg cells suppress T cell responses directed against the hepatitis viruses, they also play a protective role by downregulating immune-mediated mechanisms of liver damage. However, it is unclear whether these different roles are attributed to identical Treg populations or distinct Treg subpopulations. In addition, it remains to be elucidated whether these two different roles are mediated by identical suppression mechanisms or by distinct mechanisms. A more detailed understanding of Treg cells in hepatitis viral infections will broaden our knowledge of immune responses and immunopathology in viral hepatitis and may provide new therapeutic targets for clinical applications.
  61 in total

1.  A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood.

Authors:  S Yamagiwa; J D Gray; S Hashimoto; D A Horwitz
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

2.  Inducing and expanding regulatory T cell populations by foreign antigen.

Authors:  Karsten Kretschmer; Irina Apostolou; Daniel Hawiger; Khashayarsha Khazaie; Michel C Nussenzweig; Harald von Boehmer
Journal:  Nat Immunol       Date:  2005-10-23       Impact factor: 25.606

Review 3.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  From vanilla to 28 flavors: multiple varieties of T regulatory cells.

Authors:  Ethan M Shevach
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

Review 5.  Natural regulatory T cells and persistent viral infection.

Authors:  Shuo Li; Eric J Gowans; Claire Chougnet; Magdalena Plebanski; Ulf Dittmer
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

6.  Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.

Authors:  Dongping Xu; Junliang Fu; Lei Jin; Hui Zhang; Chunbao Zhou; Zhengsheng Zou; Jing-Min Zhao; Bin Zhang; Ming Shi; Xilai Ding; Zirong Tang; Yang-Xin Fu; Fu-Sheng Wang
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

7.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 8.  Immune responses and immunopathology in acute and chronic viral hepatitis.

Authors:  Eui-Cheol Shin; Pil Soo Sung; Su-Hyung Park
Journal:  Nat Rev Immunol       Date:  2016-07-04       Impact factor: 53.106

Review 9.  Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.

Authors:  Barbara Rehermann; Antonio Bertoletti
Journal:  Hepatology       Date:  2015-02       Impact factor: 17.425

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  21 in total

1.  Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients.

Authors:  Shu-Fen Wu; Chih-Wei Tseng; Yun-Che Ho; Yen-Chun Chen; Ping-Hung Ko; Yi-Ting He; Kuo-Chih Tseng
Journal:  Dig Dis Sci       Date:  2019-09-26       Impact factor: 3.199

2.  Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma.

Authors:  Hana Park; Jae Hyung Jung; Min Kyung Jung; Eui-Cheol Shin; Simon Weonsang Ro; Jeon Han Park; Do Young Kim; Jun Yong Park; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2020-02-18       Impact factor: 6.047

3.  Interleukin-10 Modulation of Virus Clearance and Disease in Mice with Alphaviral Encephalomyelitis.

Authors:  Nina M Martin; Diane E Griffin
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

4.  Changes in Serum Interferon Gamma and Interleukin-10 in Relation to Direct-Acting Antiviral Therapy of Chronic Hepatitis C Genotype 4: A Pilot Study.

Authors:  Mohamed M Nabeel; Rania K Darwish; Wafaa Alakel; Rabab Maher; Hossam Mostafa; Ahmed Hashem; Mohamed Elbeshlawy; Amr Abul-Fotouh; Hend I Shousha; Mohamad Saeed Marie
Journal:  J Clin Exp Hepatol       Date:  2021-06-25

5.  Longitudinal assessment of T cell inhibitory receptors in liver transplant recipients and their association with posttransplant infections.

Authors:  Krupa R Mysore; Rafik M Ghobrial; Sunil Kannanganat; Laurie J Minze; Edward A Graviss; Duc T Nguyen; Katherine K Perez; Xian C Li
Journal:  Am J Transplant       Date:  2017-11-20       Impact factor: 8.086

6.  Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C.

Authors:  Geórgia Nascimento Saraiva; Natalia Fonseca do Rosário; Thalia Medeiros; Paulo Emílio Côrrea Leite; Gilmar de Souza Lacerda; Thaís Guaraná de Andrade; Elzinandes Leal de Azeredo; Petronela Ancuta; Jorge Reis Almeida; Analúcia Rampazzo Xavier; Andrea Alice Silva
Journal:  Mediators Inflamm       Date:  2018-05-27       Impact factor: 4.711

7.  A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B.

Authors:  Allan Ma; Bruce Motyka; Klaus Gutfreund; Yuenian Eric Shi; Rajan George
Journal:  Hum Vaccin Immunother       Date:  2019-12-12       Impact factor: 3.452

8.  The Cytotoxic Activity of Natural Killer Cells Is Suppressed by IL-10+ Regulatory T Cells During Acute Retroviral Infection.

Authors:  Elisabeth Littwitz-Salomon; Anna Malyshkina; Simone Schimmer; Ulf Dittmer
Journal:  Front Immunol       Date:  2018-08-27       Impact factor: 7.561

9.  Expression of Foxp3 in renal tissue of patients with HBV-associated glomerulonephritis and their clinical and pathological characteristics.

Authors:  Wenge Zhao; Yanli Ma; Mingmin Wang; Changhe Shi; Jianping Sun; Kaiqiu Chu; Chuansheng Liu
Journal:  Exp Ther Med       Date:  2017-09-05       Impact factor: 2.447

Review 10.  A juggernaut of innate & adaptive immune cells in chronic hepatitis C.

Authors:  Shallu Tomer; Sunil K Arora
Journal:  Indian J Med Res       Date:  2020-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.